×
About 1,108 results

ALLMedicine™ Restrictive Cardiomyopathy Center

Research & Reviews  547 results

Practical recommendations for the diagnosis and management of transthyretin cardiac amy...
https://doi.org/10.1007/s10741-020-10062-w 10.1161/CIRCULATIONAHA.116.024438 10.1161/CIRCULATIONAHA.108.843334 10.1016/j.jchf.2013.11.004 10.1093/eurheartj/ehx350 10.1093/eurheartj/ehv338 10.1093/eurheartj/ehx043 10.1016/j.jacc.2016.06.053 10.1111/bjh.12286 10.1182/bloodadvances.2019000147 10.1111/bjh.13805 10.3109/13506129.2011.574354032 10.3324/haematol.2014.104109 10.1016/j.jacc.2015.09.075 10.1038/s41582-019-0210-4 10.1007/s004390050199 10.1056/NEJM199702133360703 10.1093/eurheartj/ehs123 10.1161/CIRCULATIONAHA.111.078915 10.1016/j.jacc.2019.04.003 10.1016/j.jcmg.2014.03.004 10.1016/j.ijcard.2018.06.006 10.1161/JAHA.113.000098 10.1161/CIRCULATIONAHA.115.018852 10.1016/j.jacc.2016.06.033 10.1093/eurheartj/ehs397 10.1093/eurheartj/ehu284 10.1001/jama.2017.9236 10.1038/modpathol.2014.102 10.1016/j.jacc.2018.07.092 10.3109/13506129.2013.825240 10.1093/eurheartj/ehx589 10.1309/LYWM47K2L8XYFFB3 10.1056/NEJMoa054494 10.1038/bcj.2017.97 10.3324/haematol.2018.190405 10.1002/ajh.25440 10.1080/13506129.2018.1436048 10.1016/j.carpath.2012.09.001 10.1161/CIRCULATIONAHA.116.021612 10.2215/CJN.02290508 10.1016/j.amjcard.2014.07.026 10.1136/openhrt-2015-000289 10.1016/j.jacc.2016.03.596 10.1093/eurheartj/ehr383 10.1161/CIRCULATIONAHA.113.006242 10.1016/0002-9149(82)90270-3 10.1016/S0735-1097(12)61587-3 10.1093/ehjci/jeu158 10.1007/s11886-019-1094-z 10.1007/s12574-015-0249-1 10.1016/j.acvd.2013.06.051 10.1016/j.tcm.2017.07.004 10.1016/j.echo.2008.11.013 10.1161/01.CIR.0000068313.67758.4F 10.1016/j.echo.2007.02.025 10.1080/13506120902879681 10.1016/j.amjcard.2008.09.102 10.1016/j.jcmg.2015.05.014 10.1161/01.RES.0000126569.75419.74 10.1073/pnas.0912263107 10.1136/heartjnl-2012-302353 10.1161/CIRCIMAGING.113.000683 10.1161/CIRCIMAGING.116.005588 10.1136/heartjnl-2015-308657 10.1080/13506129.2018.1493989 10.1016/j.jacc.2017.05.053 10.1016/j.jacc.2007.10.049 10.1016/j.jcmg.2013.10.008 10.1016/j.jcmg.2019.03.026 10.1016/0002-8703(82)90331-3 10.1016/S0002-9149(83)80140-4 10.1001/archinte.1987.00370060035007 10.1007/s11886-019-1180-2 10.3109/13506129.2015.1072089 10.1161/CIRCIMAGING.112.000132 10.1016/j.jacc.2005.05.073 10.1007/s00259-018-4013-4 10.1016/j.jcmg.2011.03.016 10.1007/s12350-019-01760-6 10.1007/s002590050406 10.1016/S0735-1097(96)00438-X 10.1161/CIRCIMAGING.112.000367 10.1007/s00259-014-2787-6 10.3389/fcvm.2015.00023 10.2967/jnumed.115.169870 10.2967/jnumed.111.102053 10.1016/j.jcmg.2014.09.018 10.1007/s12350-018-01551-5 10.1002/1097-0339(200103)24:3<181::AID-DC1037>3.0.CO;2-D 10.1182/blood-2014-11-609883 10.1097/PAS.0b013e3182263d74 10.1182/blood-2009-07-230722 10.1080/13506129.2018.1449744 10.1016/j.amjcard.2020.07.034 10.1016/j.jacep.2020.01.004 10.1002/ehf2.12308 10.1016/j.jacc.2018.10.079 10.1161/CIRCULATIONAHA.107.697763 10.1016/j.cardfail.2019.07.233 10.1111/jce.14180 10.1161/JAHA.120.017335 10.1007/s10741-014-9462-7 10.1073/pnas.1121005109 10.1212/WNL.0b013e3182661eb1 10.1007/s12265-013-9512-x 10.1080/13506129.2017.1357545 10.1056/NEJMoa1805689 10.1038/labinvest.3700059 10.1001/jama.2013.283815 10.1093/eurheartj/ehz298 10.1111/j.1751-7133.2012.00303.x 10.1080/13506129.2018.1519507 10.1096/fj.02-0764com 10.1016/j.bbadis.2008.05.005 10.1186/1479-5876-8-74 10.3109/13506129.2012.678508 10.1056/NEJMoa1208760 10.1186/s13023-015-0326-6 10.1056/NEJMoa1716153 10.1161/CIRCULATIONAHA.118.035831 10.1080/13506129.2016.1191458 10.1056/NEJMoa1716793 10.1080/13506129.2019.1685487 10.1038/srep25080 10.1021/acs.jmedchem.8b00817 10.1126/science.1062245 10.1016/j.jacc.2019.03.012 10.1111/j.1399-0004.1991.tb03085.x 10.1097/TP.0000000000000574 10.1111/j.1600-6143.2006.01585.x 10.1016/j.healun.2015.10.023 10.1097/TP.0b013e3181ac60db 10.1097/TP.0000000000002240 10.1186/s12968-018-0478-3
Heart Failure Reviews; Bistola V, Parissis J et. al.

Jan 16th, 2021 - Cardiac amyloidosis (CA) is an infiltrative restrictive cardiomyopathy caused by accumulation in the heart interstitium of amyloid fibrils formed by misfolded proteins. Most common CA types are light chain amyloidosis (AL) caused by monoclonal imm...

Endomyocardiofibrosis: A Systematic Review.
https://doi.org/10.1016/j.cpcardiol.2020.100784
Current Problems in Cardiology; Scatularo CE, Posada Martínez EL et. al.

Jan 8th, 2021 - Endomyocardiofibrosis was described first time in Uganda as an infrequent restrictive cardiomyopathy with a poor prognosis, characterized by fibrosis of the ventricular subendocardium and severe restrictive physiology leading to difficult therapeu...

Management of Heart Failure in Cardiac Amyloidosis Using an Ambulatory Diuresis Clinic.
https://doi.org/10.1016/j.ahj.2020.12.009
American Heart Journal; Vaishnav J, Hubbard A et. al.

Dec 22nd, 2020 - Recurrent congestion in cardiac amyloidosis (CA) remains a management challenge, often requiring high dose diuretics and frequent hospitalizations. Innovative outpatient strategies are needed to effectively manage HF in patients with CA. Ambulator...

Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of sys...
https://doi.org/10.1111/joim.13222
Journal of Internal Medicine References; Eldhagen P, Berg S et. al.

Dec 4th, 2020 - Wild-type transthyretin (ATTRwt) amyloidosis is the most common systemic amyloidosis in Western countries and manifests mainly as progressive restrictive cardiomyopathy. To study the prevalence of ATTR deposits in ligament tissue in patients under...

Cardiac Amyloidosis Detected on Imaging of Patients with Heart Failure.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669957
The American Journal of Case Reports; Roginić S, Vinter O et. al.

Nov 11th, 2020 - BACKGROUND Amyloidosis is a multisystem disease caused by deposition of dysfunctional protein-amyloid-in various organs. The heart is commonly involved, especially in primary (AL) and transthyretin (ATTR) amyloidosis. Most patients present with re...

see more →

Clinicaltrials.gov  555 results

Practical recommendations for the diagnosis and management of transthyretin cardiac amy...
https://doi.org/10.1007/s10741-020-10062-w 10.1161/CIRCULATIONAHA.116.024438 10.1161/CIRCULATIONAHA.108.843334 10.1016/j.jchf.2013.11.004 10.1093/eurheartj/ehx350 10.1093/eurheartj/ehv338 10.1093/eurheartj/ehx043 10.1016/j.jacc.2016.06.053 10.1111/bjh.12286 10.1182/bloodadvances.2019000147 10.1111/bjh.13805 10.3109/13506129.2011.574354032 10.3324/haematol.2014.104109 10.1016/j.jacc.2015.09.075 10.1038/s41582-019-0210-4 10.1007/s004390050199 10.1056/NEJM199702133360703 10.1093/eurheartj/ehs123 10.1161/CIRCULATIONAHA.111.078915 10.1016/j.jacc.2019.04.003 10.1016/j.jcmg.2014.03.004 10.1016/j.ijcard.2018.06.006 10.1161/JAHA.113.000098 10.1161/CIRCULATIONAHA.115.018852 10.1016/j.jacc.2016.06.033 10.1093/eurheartj/ehs397 10.1093/eurheartj/ehu284 10.1001/jama.2017.9236 10.1038/modpathol.2014.102 10.1016/j.jacc.2018.07.092 10.3109/13506129.2013.825240 10.1093/eurheartj/ehx589 10.1309/LYWM47K2L8XYFFB3 10.1056/NEJMoa054494 10.1038/bcj.2017.97 10.3324/haematol.2018.190405 10.1002/ajh.25440 10.1080/13506129.2018.1436048 10.1016/j.carpath.2012.09.001 10.1161/CIRCULATIONAHA.116.021612 10.2215/CJN.02290508 10.1016/j.amjcard.2014.07.026 10.1136/openhrt-2015-000289 10.1016/j.jacc.2016.03.596 10.1093/eurheartj/ehr383 10.1161/CIRCULATIONAHA.113.006242 10.1016/0002-9149(82)90270-3 10.1016/S0735-1097(12)61587-3 10.1093/ehjci/jeu158 10.1007/s11886-019-1094-z 10.1007/s12574-015-0249-1 10.1016/j.acvd.2013.06.051 10.1016/j.tcm.2017.07.004 10.1016/j.echo.2008.11.013 10.1161/01.CIR.0000068313.67758.4F 10.1016/j.echo.2007.02.025 10.1080/13506120902879681 10.1016/j.amjcard.2008.09.102 10.1016/j.jcmg.2015.05.014 10.1161/01.RES.0000126569.75419.74 10.1073/pnas.0912263107 10.1136/heartjnl-2012-302353 10.1161/CIRCIMAGING.113.000683 10.1161/CIRCIMAGING.116.005588 10.1136/heartjnl-2015-308657 10.1080/13506129.2018.1493989 10.1016/j.jacc.2017.05.053 10.1016/j.jacc.2007.10.049 10.1016/j.jcmg.2013.10.008 10.1016/j.jcmg.2019.03.026 10.1016/0002-8703(82)90331-3 10.1016/S0002-9149(83)80140-4 10.1001/archinte.1987.00370060035007 10.1007/s11886-019-1180-2 10.3109/13506129.2015.1072089 10.1161/CIRCIMAGING.112.000132 10.1016/j.jacc.2005.05.073 10.1007/s00259-018-4013-4 10.1016/j.jcmg.2011.03.016 10.1007/s12350-019-01760-6 10.1007/s002590050406 10.1016/S0735-1097(96)00438-X 10.1161/CIRCIMAGING.112.000367 10.1007/s00259-014-2787-6 10.3389/fcvm.2015.00023 10.2967/jnumed.115.169870 10.2967/jnumed.111.102053 10.1016/j.jcmg.2014.09.018 10.1007/s12350-018-01551-5 10.1002/1097-0339(200103)24:3<181::AID-DC1037>3.0.CO;2-D 10.1182/blood-2014-11-609883 10.1097/PAS.0b013e3182263d74 10.1182/blood-2009-07-230722 10.1080/13506129.2018.1449744 10.1016/j.amjcard.2020.07.034 10.1016/j.jacep.2020.01.004 10.1002/ehf2.12308 10.1016/j.jacc.2018.10.079 10.1161/CIRCULATIONAHA.107.697763 10.1016/j.cardfail.2019.07.233 10.1111/jce.14180 10.1161/JAHA.120.017335 10.1007/s10741-014-9462-7 10.1073/pnas.1121005109 10.1212/WNL.0b013e3182661eb1 10.1007/s12265-013-9512-x 10.1080/13506129.2017.1357545 10.1056/NEJMoa1805689 10.1038/labinvest.3700059 10.1001/jama.2013.283815 10.1093/eurheartj/ehz298 10.1111/j.1751-7133.2012.00303.x 10.1080/13506129.2018.1519507 10.1096/fj.02-0764com 10.1016/j.bbadis.2008.05.005 10.1186/1479-5876-8-74 10.3109/13506129.2012.678508 10.1056/NEJMoa1208760 10.1186/s13023-015-0326-6 10.1056/NEJMoa1716153 10.1161/CIRCULATIONAHA.118.035831 10.1080/13506129.2016.1191458 10.1056/NEJMoa1716793 10.1080/13506129.2019.1685487 10.1038/srep25080 10.1021/acs.jmedchem.8b00817 10.1126/science.1062245 10.1016/j.jacc.2019.03.012 10.1111/j.1399-0004.1991.tb03085.x 10.1097/TP.0000000000000574 10.1111/j.1600-6143.2006.01585.x 10.1016/j.healun.2015.10.023 10.1097/TP.0b013e3181ac60db 10.1097/TP.0000000000002240 10.1186/s12968-018-0478-3
Heart Failure Reviews; Bistola V, Parissis J et. al.

Jan 16th, 2021 - Cardiac amyloidosis (CA) is an infiltrative restrictive cardiomyopathy caused by accumulation in the heart interstitium of amyloid fibrils formed by misfolded proteins. Most common CA types are light chain amyloidosis (AL) caused by monoclonal imm...

Endomyocardiofibrosis: A Systematic Review.
https://doi.org/10.1016/j.cpcardiol.2020.100784
Current Problems in Cardiology; Scatularo CE, Posada Martínez EL et. al.

Jan 8th, 2021 - Endomyocardiofibrosis was described first time in Uganda as an infrequent restrictive cardiomyopathy with a poor prognosis, characterized by fibrosis of the ventricular subendocardium and severe restrictive physiology leading to difficult therapeu...

Management of Heart Failure in Cardiac Amyloidosis Using an Ambulatory Diuresis Clinic.
https://doi.org/10.1016/j.ahj.2020.12.009
American Heart Journal; Vaishnav J, Hubbard A et. al.

Dec 22nd, 2020 - Recurrent congestion in cardiac amyloidosis (CA) remains a management challenge, often requiring high dose diuretics and frequent hospitalizations. Innovative outpatient strategies are needed to effectively manage HF in patients with CA. Ambulator...

Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of sys...
https://doi.org/10.1111/joim.13222
Journal of Internal Medicine References; Eldhagen P, Berg S et. al.

Dec 4th, 2020 - Wild-type transthyretin (ATTRwt) amyloidosis is the most common systemic amyloidosis in Western countries and manifests mainly as progressive restrictive cardiomyopathy. To study the prevalence of ATTR deposits in ligament tissue in patients under...

Cardiac Amyloidosis Detected on Imaging of Patients with Heart Failure.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669957
The American Journal of Case Reports; Roginić S, Vinter O et. al.

Nov 11th, 2020 - BACKGROUND Amyloidosis is a multisystem disease caused by deposition of dysfunctional protein-amyloid-in various organs. The heart is commonly involved, especially in primary (AL) and transthyretin (ATTR) amyloidosis. Most patients present with re...

see more →

News  3 results

How to tell constrictive pericarditis from mimickers
https://www.mdedge.com/familymedicine/article/97069/heart-failure/how-tell-constrictive-pericarditis-mimickers/page/0/2
Cardiology News;

Feb 11th, 2015 - A patient with constrictive pericarditis will have enhanced ventricular interaction arising from the restraint imposed by a rigid, diseased pericardium. That’s crucial.

Echo Aids Diagnosis of Constrictive Pericarditis
https://www.mdedge.com/cardiology/article/41523/imaging/echo-aids-diagnosis-constrictive-pericarditis
Bruce Jancin

SNOWMASS, COLO. — Demonstration of enhanced ventricular interaction upon hemodynamic cardiac catheterization is a novel diagnostic criterion for constrictive pericarditis, with far greater predictive accuracy than that of the classic hemodynamic c.

Untangling the Physiology of Transthyretin Cardiac Amyloidosis by Leveraging Echocardiographically Derived Pressure–Volume Indices
https://www.medscape.com/viewarticle/929217

Transthyretin cardiac amyloidosis (ATTR-CA) is the most common aetiology of restrictive cardiomyopathy in older adults and is increasingly being recognized by providers due the advent of non-invasive diagnostic methods[1] and the development of ef...

see more →

Patient Education  3 results see all →